Presented at #LIVES2025: In the EVERDAC trial involving patients with shock, results for death at day 28 indicated that management without early arterial catheter insertion was noninferior to early catheter insertion. Full trial results: https://t.co/N5ou9POC0r Editorial: A

New Episode of @ASTCT Titans of Transplant, and we’re honored to have CAR-T expert Dr. Sattva Neelapu from @MDAndersonNews We talk about past, present and future of this therapy, lots of wisdom and insight you don’t want to miss it #bmtsm #CARtcell https://t.co/heG2TrwN33

#FDA approves a treatment for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. https://t.co/YXQXJ2bRK0

Encouraging real world experience (N=9) from @MayoClinic on BCMA-directed CAR T in AL #amyloidosis. ➡️ 89% CRS, 22% G3+ ➡️ 1 IEC-HS, 1 CN palsy ➡️ 75% hematologic CR, 1 VGPR ➡️ 1-yr PFS and OS of 100% ➡️ both cardiac and renal responses seen https://t.co/Ua4gvogljh

CAR #HEMATOTOX is associated with brexu-cel response, survival, and neutrophil recovery in #ALLsm. Great collaboration with @MSKCancerCenter Yannis Valtis & Jae Park, and #ROCCA consortium @StanfordCancer @LoriMuffly @UChicagoLeuk @RoloffGreg. @DukeCancer https://t.co/SW3mEvE5AM

“Every physician carries within himself a small cemetery, where from time to time he goes to pray.” — René Leriche The guilt is real. Each name finds its place there, quiet and heavy. What surprises me still are the families who meet loss with gratitude—who somehow thank you

Congratulations to the newly announced Nobel Prize recipients, Drs. Brunkow, Ramsdell and Sakaguchi for their work identifying regulatory T cells. If you’re looking to learn more about Tregs, join us at #SITC25 or the upcoming Deep Dive webinar.

An interesting study in @NEJM showing the feasibility of an in vivo CD19-directed CAR T for refractory Systemic Lupus Erythematosus. Fascinating work in the field of in vivo generation of cell therapies, now applied to autoimmunity. #CART #lupus https://t.co/s6WOpumf7c

Congrats to @CanerSaygin and several leukemia program faculty including @Anand_88_Patel @DrWendyStock @myeloidmalig @AyaOncologist @michaelwd_hem on this effort characterizing outcomes in TP53m ALL https://t.co/WMKdKYdMkO

I was lucky to lead this @CIBMTR analysis just published in @AjHematology 👇 https://t.co/3oDrO4k96j 🔑 findings: 💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS

Early View | Haematologica https://t.co/F3vHTQBjOp Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) led

LLS is rebranding as Blood Cancer United on Aug 28 to reflect support for all 100+ blood cancers. 🩸 Broader reach, unified purpose 🩸 New name, same mission @LLSusa https://t.co/39C1eQp9aa #HemOnc #BloodCancer

New article alert! 🚨🚨 Dr. @Anand_88_Patel and 3rd year @UCHemOncFellows Dr. Yates are published in @Haematologica sharing the results of the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)! https://t.co/zu9vzEpli6

Established Investigators need to rank in the 4th percentile, whereas Early Investigators need to be in the 10th percentile. This means that among 80 reviews in a study section, only 3 will be below the 4th percentile.

In the latest ASTCT Talks episode, Dr. Shernan Holtan sits down with renowned leader, mentor & pioneer in cell therapy & transplantation, Dr. Daniel Weisdorf. Listen now on the ASTCT website or wherever you access podcasts: https://t.co/4uA1EqRmfC

Congratulations to @DukeCancer faculty Dr. Yubin Kang for his new @CancerResearch CLIP award studying how targeting SK2 can enhance CAR T cell therapy efficacy in multiple myeloma #mmsm https://t.co/eOFcea9ahg

Don’t let the name fool you—we are here for all blood cancers, from A to Z (AML to Waldenström’s)